NASDAQ:DRRX - DURECT Stock Price, Forecast & News

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

DURECT Co. (NASDAQ:DRRX) posted its earnings results on Monday, November, 4th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.03. The specialty pharmaceutical company had revenue of $10.76 million for the quarter, compared to analysts' expectations of $7.78 million. DURECT had a negative return on equity of 119.34% and a negative net margin of 105.07%. View DURECT's Earnings History.

DURECT is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for DURECT.

3 Wall Street analysts have issued twelve-month target prices for DURECT's shares. Their forecasts range from $2.10 to $5.50. On average, they expect DURECT's stock price to reach $4.20 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for DURECT.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT.

Headlines about DRRX stock have trended negative on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DURECT earned a news impact score of -2.5 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for DURECT.

DURECT saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,120,000 shares, an increase of 30.8% from the December 15th total of 3,150,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 3.7 days. Currently, 2.6% of the company's stock are short sold. View DURECT's Current Options Chain.

Some companies that are related to DURECT include Insmed (INSM), Pacira Biosciences (PCRX), Tricida (TCDA), Arvinas (ARVN), Akcea Therapeutics (AKCA), Constellation Pharmaceuticals (CNST), Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Forty Seven (FTSV), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA) and Intra-Cellular Therapies (ITCI).

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Geron (GERN), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Inovio Pharmaceuticals (INO) and PTC Therapeutics (PTCT).

DURECT's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.06%), Beirne Wealth Consulting Services LLC (0.86%), Assenagon Asset Management S.A. (0.05%) and Alpine Global Management LLC (0.05%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT.

DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for DURECT.

DRRX stock was acquired by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC and Alpine Global Management LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT.

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRRX stock can currently be purchased for approximately $2.51.

DURECT has a market capitalization of $482.83 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT.

The official website for DURECT is http://www.durect.com/.

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.